Table 2.
Group 1 | Group 2 | Group 3 | Group 4 | |
---|---|---|---|---|
Surveyed pre-diagnosis | Surveyed post-diagnosis | |||
| ||||
MA (Unweighted n=16,222) |
FFS (Unweighted n=15,647) |
MA (Unweighted n=42,834) |
FFS (Unweighted n=42,032) |
|
| ||||
Point estimates | ||||
SCIBI z-score - mean | −0.19 | −0.23 | 0.07 | 0.13 |
Median | −0.28 | −0.47 | −0.13 | −0.42 |
Range | −0.50 to 4.00 | −0.50 to 6.00 | −0.50 to 8.12 | −0.50 to 13.32 |
SF-12 Physical Component (v12) - mean | 41.3 | 38.3 | 39.2 | 37.1 |
SF-12 Mental Component (v12) - mean | 54.4 | 52.5 | 53.5 | 52.6 |
Comorbidity count - mean | 0.85 | 0.89 | 1.4 | 1.5 |
Percentages | ||||
Poor/fair general health status | 25.7 | 31.7 | 29.9 | 33.7 |
Poor/fair mental health status | 9.3 | 11.9 | 11.1 | 11.4 |
Depression (PHQ-2 ≥ 3) | 29.7 | 36.1 | 32.7 | 37.7 |
Proxy respondent or assistance | 12.0 | 13.6 | 13.3 | 13.5 |
Has had a condition/problem lasting 3+ months | 91.3 | 92.8 | 92.0 | 93.7 |
Current smoker | 14.8 | 15.5 | 8.6 | 8.6 |
Physical condition interferes with independence | 18.8 | 23.8 | 22.5 | 27.1 |
Need help with personal care | 6.8 | 9.2 | 9.5 | 11.3 |
Need assistance with routine tasks | 16.9 | 22.1 | 20.9 | 25.7 |
Activity limitations | ||||
Bathing | 11.5 | 14.2 | 13.4 | 14.9 |
Dressing | 8.9 | 11.4 | 11.0 | 12.0 |
Eating | 4.8 | 5.4 | 5.9 | 6.2 |
Getting in/out of chairs | 18.0 | 21.0 | 19.0 | 21.4 |
Walking | 27.8 | 32.6 | 29.5 | 31.7 |
Using the toilet | 7.0 | 8.2 | 8.4 | 9.0 |
Climbing stairs | 52.3 | 62.8 | 56.8 | 65.6 |
Moderate activities | 47.8 | 59.1 | 52.6 | 61.8 |
Social activities | 7.2 | 11.2 | 9.3 | 11.5 |
Pain interferes | 18.2 | 25.2 | 19.2 | 25.8 |
Has a lot of energy a little/none of the time | 18.8 | 25.4 | 24.5 | 29.0 |
Specific conditions reported | ||||
Heart attack or angina | 23.9 | 28.0 | 25.0 | 27.7 |
Stroke | 9.6 | 9.6 | 10.6 | 10.3 |
COPD | 20.0 | 21.3 | 19.6 | 20.0 |
Diabetes | 32.4 | 31.4 | 34.0 | 30.4 |
Cancer | 7.8 | 9.6 | 70.9 | 73.9 |
2+ self-reported chronic conditions | 17.6 | 18.9 | 15.7 | 15.5 |
Cancer-specific clinical characteristics | Not used | |||
Stage at diagnosis | ||||
In situ | 8.9 | 9.8 | ||
Local | 44.0 | 43.9 | ||
Regional | 12.8 | 12.6 | ||
Distant | 4.4 | 4.8 | ||
N/A, unknown, or unstaged | 1.7 | 2.0 | ||
Missing | 28.3 | 27.0 | ||
Cancer site | ||||
Bladder | 4.6 | 5.0 | ||
Breast | 23.0 | 22.4 | ||
Colorectal | 4.5 | 4.5 | ||
Lung | 3.9 | 4.2 | ||
Prostate | 24.5 | 23.4 | ||
Renal | 2.3 | 2.4 | ||
Skin (melanoma) | 6.9 | 7.8 | ||
Other | 30.2 | 30.4 | ||
Primary/first cancer is malignant* | 83.5 | 82.4 |
Source: Authors’ analysis of SEER-CAHPS, 2007–2013. Unweighted percentages of non-missing responses shown. FFS: fee-for-service; MA: Medicare Advantage; N/A: not applicable; PHQ-2: Patient Health Questionnaire-2 question version; SF-12: the Medical Outcomes Study Short Form - 12 question version.
People with benign tumors were included in sample.